AdAlta completes enrolment for AD-214 fibrosis safety trial | News Direct

AdAlta completes enrolment for AD-214 fibrosis safety trial

AdAlta Ltd
News release by AdAlta Ltd

facebook icon linkedin icon twitter icon pinterest icon email icon Melbourne, Victoria | September 21, 2023 12:15 PM Eastern Daylight Time

AdAlta Ltd (ASX:1AD) CEO Dr Tim Oldham tells Proactive the company has wrapped up the enrolment of healthy volunteers for its AD-214 Phase 1 extension study, and early indications are that it is well tolerated. The aim of the trial is to evaluate the safety of AD-214, the company’s flagship candidate for treating fibrotic diseases including Idiopathic Pulmonary Fibrosis.

Oldham said: “We are grateful to all the volunteers that have participated in this Phase 1 extension study.

“The data being generated continues to show that AD-214 is well tolerated and is also helping to inform dosing regimens and the broader protocol for our coming Phase 2 study for AD-214.”



Contact Details


Proactive Investors


Jonathan Jackson


+61 413 713 744

project media


AdAlta LtdbiotechAsxproactiveAustraliaproactiveInvestors